bioAffinity Technologies' noninvasive diagnostic shifted the course of care from watchful waiting for up to 5 years to confirmed malignancy and immediate treatment

bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)),a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today released another compelling case study in which its flagship product, CyPath® Lung, identified cancer in a patient with an incidental finding of ground-glass lung nodules.

Ground-glass nodules appear in imaging as hazy gray areas distinct from solid nodules. Clinicians often find them challenging to assess because they can remain stable for many years, often mimic benign lesions caused by inflammation or fibrosis, and typically do not light up on PET scans.

• No comments yet. Be the first to comment!